Glioma is often referred to as one of the most dreadful central nervous system (CNS)-specific
tumors with rapidly-proliferating cancerous glial cells, accounting for nearly half of the brain …

Gliomas constitute about 80% of brain tumors and have a meager two-year survival rate.
The treatment options available are very few because of poor prognosis and a lack of …

The treatment of glioblastoma has limited clinical progress over the past decade, partly due
to the lack of effective drug delivery strategies across the blood-brain-tumor barrier …

Pharmacological treatment of gliomas and other brain-infiltrating tumors remains
challenging due to limited delivery of most therapeutics across the blood–brain barrier …

Translation of novel therapies for brain cancer into clinical practice is of the utmost
importance as primary brain tumors are responsible for more than 200,000 deaths …

Due to their biocompatibility, non-toxicity, and surface-conjugation capabilities, liposomes
are effective nanocarriers that can encapsulate chemotherapeutic drugs and facilitate …

The current medical reality of cancer gene therapy is reflected by more than ten approved
products on the global market, including oncolytic and other viral vectors and CAR T-cells as …

Indocyanine green (ICG) is a water-soluble dye that was approved by the FDA for
biomedical purposes in 1956. Initially used to measure cardiocirculatory and hepatic …

Fluorescence-guided surgery (FGS) allows surgeons to have improved visualization of
tumor tissue in the operating room, enabling maximal safe resection of malignant brain …

The blood–brain barrier (BBB) is the interface between the central nervous system and
systemic circulation. It tightly regulates what enters and is removed from the brain …